Kornimate/medical-research-clean huggingface dataset:
low carb vs normal carb in pregnancy

Conditions: Gestational Diabetes

Summary: the overall purpose of this intervention study is to examine whether low-carbohydrate dietary intervention will prevent the development of gestational diabetes mellitus (gdm) in high-risk pregnant women. the results of this study should help further our understanding of how pregnant women can help prevent gestational diabetes mellitus. we hypothesize that a lower carbohydrate diet will prevent the development of gdm.


Eligibility criteria:
inclusion criteria: * 18 - 40 years old * bmi \> 30 and/or history of gestational diabetes mellitus * currently in first trimester of pregnancy with single fetus (e.g. not twins, triplets, etc.) * newborns of current participants exclusion criteria: * diabetes (types 1 and 2) * history of major chronic disease or blood clotting disorders (e.g., cancer, heart disease, kidney disease, hypertension) * known fetal anomaly * history of eating disorders * current use of medications that affect appetite or insulin secretion/sensitivity (e.g. stimulants) * current use of illegal substances, antipsychotic or opioid substitution medications, alcohol, or tobacco
multi-site, post-market study of the iconacy i-hip system

Conditions: Degenerative Joint Disease

Summary: the purpose of this study is to evaluate the use and efficacy of the i-hip for primary total hip replacement surgery.


Eligibility criteria:
inclusion criteria: * a candidate for primary hip replacement on this operative hip. * is 30 to 80 years of age. * has hip joint disease related to one or more of the following: * degenerative joint disease, (including osteoarthritis or post-traumatic arthritis) * avascular necrosis (avn). * will be available for evaluation for the duration of the study. * is able and willing to speak and read english, read and sign the informed consent, fill out the womac and patient satisfaction questionnaires, and follow all study procedures. exclusion criteria: * is younger than 30 years of age or older than 80 years of age. * has undergone partial hip replacement or previous orif (open reduction internal fixation of femur or acetabulum). * has undergone total hip replacement on this hip in the past (no revisions allowed in study). * infection, or history of infection, acute or chronic, in the hip joint, or acute or chronic unresolved systemic infection. * is currently experiencing radicular pain from the spine down operative leg. * has participated in an ide/ind clinical investigation with an investigational product in the last three months, or is involved in any personal injury litigation, medical-legal or worker's compensation claim. * is a known drug or alcohol abuser or has a psychological disorder that could affect the ability to complete patient reported questionnaires. * has been diagnosed with fibromyalgia or has a significant neurological or musculoskeletal disorder or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, charcot disease). * has been diagnosed with paget's disease or congenital hip deformity (dysplasia and/or dislocation). * is suffering from inflammatory arthritis (e.g. rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, systemic lupus erythematosus, etc.) * is obese: (defined for this study as having a bmi\>45). * has insufficient bone quality. * has loss of ligamentous structures. * has materials sensitivity. * is currently a prisoner. * is pregnant or lactating. * has a contralateral amputation. * has a medical condition with less than 2 years of life expectancy.

Keywords: hip arthroplasty arthroplasties prosthesis iconacy osteoarthritis arthritis tha thr djd
effect of age on latanoprost 0.005% in patients with glaucoma

Conditions: Glaucoma

Summary: latanoprost is a commonly used treatment for glaucoma. because of its mechanism of action, it is plausible that the age of a patient using the medication may affect its efficacy and time of onset. we are going to study the effectiveness of latanoprost in people of different ages, to see if it changes based on the age of the patient.

latanoprost is a topical ocular hypotensive medication with a well established safety and efficacy profile. its effect is mediated by an increase in uveoscleral outflow, due to enzymatic degradation of the extracellular matrix within the ciliary muscle. since the amount of extracellular matrix within the human eye increases with age, and uveoscleral outflow decreases with age, it would be expected that there should be a difference in the efficacy of latanoprost in patients of different ages. this has not been demonstrated in studies assessing the overall effect of latanoprost across adult age groups using multivariate analysis. (camras cb et al, 1996). however, a difference in timing of onset of drug effect may get overlooked in clinical studies and in clinical practice as well, as patients tend to be seen from two to eight weeks after initiation of treatment, by which time any differences in response time may have already occurred and leveled off. to our knowledge, there are no studies specifically looking at the timing of onset of drug effect of latanoprost in different age groups. because of the theoretical plausibility of this effect based on the mechanism of action of latanoprost, this represents an opportunity to further elucidate the characteristics of this medication in a manner which has clinical and scientific relevance. our aim is thus to determine if there is a difference in timing of onset of the ocular hypotensive effect of latanoprost in glaucoma patients of different age groups.

Eligibility criteria:
inclusion criteria: * diagnosis of open angle glaucoma, * pseudoexfoliation glaucoma, pigmentary glaucoma or ocular hypertension in one or both eyes; * iop above their target pressure as determined by a glaucoma specialist; * willingness to participate in the study. exclusion criteria: * hypersensitivity to any of the components of the treatment medication; * previous use of topical prostaglandins; * documented ocular infection or intraocular inflammation within the past year; * previous filtering surgery or complicated cataract surgery; * active corneal disease; * presence of cystoid macular edema; * laser trabeculoplasty or any other ocular laser procedure within the past three months.

Keywords: latanoprost glaucoma intraocular pressure
a clinical study on lm103 injection for the treatment of advanced solid tumors

Conditions: Solid Tumor

Summary: this study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte lm103 injection in advanced solid tumor patients. the research treatment includes fludarabine and cyclophosphamide, autologous tumor infiltrating lymphocytes (tils) infusion, and interleukin-2 therapy.


Eligibility criteria:
inclusion criteria: 1. the expected survival time is not less than 6 months. 2. clinical performance status of eastern cooperative oncology group (ecog) 0-1. 3. patients with advanced solid tumors confirmed by histology or cytology: advanced melanoma, head and neck squamous cell cancer, soft tissue sarcoma and other solid tumors that have failed standard treatment regimens, cannot tolerate standard treatment, refuse or do not have standard treatment regimens available. 4. the patient has lesions that can be used for surgical resection (\>1.5 cm\^3) or biopsy puncture (no less than 6 lesions) for tils collection. 5. at least one measurable lesion as the target lesion after collecting tumor tissue from the patient (recist v1.1 criteria). 6. laboratory tests results during the screening period indicate that the subjects have sufficient organ function. exclusion criteria: 1. have a medical history of other malignant tumors other than the disease under study in the past 5 years, except for malignant tumors that can be expected to recover after treatment (including but not limited to thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer or ductal carcinoma in situ of the breast treated by radical surgery). 2. lm103 received systematic sex therapy of antineoplastic drugs (including chemotherapy, small molecule targeted drug therapy, hormone replacement therapy, etc.), or local antineoplastic therapy (such as radiotherapy, palliative radiotherapy for bone metastases\>2 weeks before the start of the study and intracranial stereotactic radiotherapy or resection of a single brain metastasis\>3 weeks before the start of the study were acceptable) within 4 weeks before lm103 infusion; or received clinical investigational drugs or equipment treatment. 3. adverse reactions caused by previous treatment have not recovered to ctcae (version 5.0) level 1 or below (excluding hair loss and neurotoxicity, which have been determined by the researchers to be irreparable and level 2 hypothyroidism for a long time). 4. previously received allogeneic hematopoietic stem cell transplantation or solid organ transplantation.
bridging the gap to improve mental health treatment utilization

Conditions: Depression; Anxiety; Adolescent Behavior; Suicidal Ideation

Summary: bridging the gap aims to improve access to effective mental health treatment in a primary care setting through utilization of single session growth mindset interventions for parents and for youths. this project will also utilize focus groups and qualitative interviews to gain feedback on a single session online intervention in a rural pediatric primary care practice.

bridging the gap purposes to collect feedback on a single session growth mindset intervention (gmi) for parents and for youths designed to instill beliefs that personal traits (including mental health problems) are malleable. feedback will also be collected to identify ways to improve implementing single session interventions (ssis) in a primary care setting as well as identifying the impact on work-flow of this gmi. patients presenting with depression and/or anxiety will all receive the gmi and will have the option of participating in focus groups/interviews pre and post-intervention to provide feedback on the intervention. providers at this rural pediatric primary care practice will also have the chance to participate in focus groups/interviews pre and post-intervention implementation. assignment of interventions: as an open trial, all participants will be assigned to the intervention arm and will receive the gmi. this study is an open trial pilot project to collect feedback on a single session growth mindset intervention (gmi) (n=25 youth/caretaker dyads). feedback from pre and post-intervention focus groups/interviews will be collected for 8 parents, 8 youth, and 8 treatment providers. the aims of the study are to: 1. collect feedback from providers, parents, and participants pre and post- gmi to identify ways to improve implementing single session interventions (ssis) in a primary care setting. 2. identify the impact on work-flow of using an online single session called growth mindset intervention in a primary care setting.

Eligibility criteria:
inclusion criteria: * patients presenting with depression and/or anxiety, as identified by the patient, parent, or provider * 10-18 years old * cbt is recommended by provider. receipt of mental health services upon enrollment will be monitored but will not preclude participation * participants must reside with a legal guardian * english speaking exclusion criteria: * participants will be excluded if they have conditions that might impair their ability to effectively engage in bridging the gap, i.e * those in a current manic episode * those in a current psychotic episode * those diagnosed with autism spectrum disorder * those who have issues with substance abuse * participants with current involvement with child welfare.

Keywords: depression pediatric primary care adolescent behavior mood disorder technology provider intervention
low-cost, noninvasive method to assess pulpal vitality

Conditions: Other Dental Disease/Condition of Teeth/Supporting Structure

Summary: the purpose of this research study is to find a new way of using light to measure the blood flow within the tooth. the researcher develop dental laser speckle imaging system tool that can use for exam condition of the tooth. this device is reliable method to provide information to dentists and endodontists during oral examination.

in additional to routine oral exam the researcher can use the laser speckle imaging system probe with low-level light shine to the problematic tooth to collect blood flow information.

Eligibility criteria:
inclusion criteria: * male or female aged 18 to 30. * have one or more teeth requiring endodontic treatment. exclusion criteria: * participation in other study within 3 months of enrollment in this study, * pregnant women.
a retrospective clinical study exploring prognostic factors in esophageal cancer patients

Conditions: Esophageal Cancer (EsC)

Summary: this single-center, retrospective, 7-year observational study aims to investigate prognostic factors in esophageal cancer patients. adults (≥18 years) with histologically confirmed esophageal cancer who received antitumor therapy between january 2017 and december 2024 were consecutively enrolled. patient-level data (clinical characteristics, routine laboratory tests, tumor information, and treatment details) were retrospectively collected from electronic medical records to analyze key factors influencing treatment efficacy.


Eligibility criteria:
inclusion criteria: 1. waiver of informed consent for deceased or lost-to-follow-up patients (january 2017-march 2024) 2. voluntary signed informed consent from surviving patients who could be contacted 3. treatment at nanfang hospital, southern medical university (january 2017-december 2024) 4. received antitumor therapy for esophageal cancer 5. eastern cooperative oncology group (ecog) performance status score of 0-2 exclusion criteria: 1. concurrent other malignancies 2. patients deemed ineligible by investigators

Keywords: prognostic factors treatment strategies efficacy comparison esophageal cancer
telerehabilitation and lymphoma patients

Conditions: Lymphoma; Rehabilitation

Summary: this study aims to examine the feasibility and effect of a home-based short-term telerehabilitation exercise intervention using heart rate monitor and internet platform in patients with lymphoma.

fifteen lymphoma cancer patients post-treatment (except adjuvant treatment) will be enrolled in the study. cardiorespiratory fitness (peak oxygen consumption), adverse events, body composition and adherence to exercise prescription will be evaluated at baseline, 12-week, and year after enrollment.

Eligibility criteria:
inclusion criteria: * lymphoma patients post-treatment (except ongoing adjuvant treatment) * post-treatment period not exceeding 3 months * internet connection at home * literacy with information and communication technology * patients who agreed with informed consent exclusion criteria: * inability to perform a cardiopulmonary exercise test * psychological severe or cognitive disorders * contraindications for cardiopulmonary exercise testing * other exercise limitations (musculoskeletal disorders) * planned intervention or operation * participants who are enrolled in or participate in other rehabilitation program * participants who plan to be or are included in other studies
alcohol withdrawal syndrome treated with adjunctive phenobarbital or ketamine

Conditions: Alcohol Withdrawal Syndrome

Summary: the goal of this study will aim to determine if adding phenobarbital or ketamine to a symptom-triggered benzodiazepine regimen decreases the rate of intensive care unit admissions during the treatment of alcohol withdrawal syndrome when compared to symptom-triggered benzodiazepine therapy alone.

the primary objective of this study is to compare phenobarbital and ketamine adjunctive therapies to lorazepam-based therapy in the treatment of acute alcohol withdrawal syndrome. it is hypothesized that the use of an alternative agent, either phenobarbital or ketamine, when used as an adjunct to symptom-triggered lorazepam therapy will significantly reduce the rate of intensive care unit admissions and thereby reduce the total cost associated with hospital admission for treatment of alcohol withdrawal syndrome. enrolled patients will be admitted to santa barbara cottage hospital where they will be monitored with continuous pulse oximetry and cardiac telemetry. they will remain hospitalized while undergoing study-guided therapy in addition to supportive care for acute alcohol withdrawal syndrome. patients will undergo standard of care therapy with lorazepam symptom-triggered therapy regardless of study participation.

Eligibility criteria:
inclusion criteria: * primary admitting diagnosis of acute alcohol withdrawal syndrome based on international statistical classification of diseases and related health problems 10th revision (icd-10), code f10.3, f10.4. exclusion criteria: * significant comorbid medical illness requiring intensive care unit admission; * pregnancy; * inability to obtain intravenous access; * child pugh class c; and * allergy to study medications (phenobarbital, ketamine, lorazepam).

Keywords: lorazepam ketamine phenobarbital
study of endothelial cell condition after cataract surgery performed using capsulorhexis or zepto

Conditions: Endothelial Cell Density Loss

Summary: this study will use images of the subjects' corneal endothelium obtained using non-invasive specular microscopy to obtain corneal endothelial cell density, the coefficient of variation in endothelial cell size, and the percentage of hexagonal endothelial cells following routine cataract surgery performed using the standard method of manual capsulorhexis compared to cataract surgery performed using zepto precision capsulotomy system.


Eligibility criteria:
inclusion criteria: * subjects consenting to undergoing phacoemulsification and iol implant surgery for the treatment of symptomatic age-related lens cataract, and then electing to undergo the study, * subjects must be willing and able to return for scheduled treatment and follow-up examinations at 1 and 3 months. exclusion criteria: * pre-existing corneal endothelium pathology * presence of guttae * narrow angle glaucoma or advanced glaucoma * psuedoexfoliation * zonular abnormalities * corneal endothelial cell density less than 1800 cells/mm2 * uveitis * anterior chamber depth less than 2.5mm or greater than 3.75mm * cataract grade locs ii \> 3 * posterior polar cataract * planned implantation of iol \> 25d * prior ocular surgery in the study eye * history of medications with potential corneal endothelial cell toxicity * any condition that in the surgeon's judgement should exclude the subject from study enrollment. * current participation in another drug or device clinical study, or participation in such a clinical study within the prior six months and during the duration of the current study
effect of upstream high bolus dose of tirofiban in primary pci for the patients with stemi on short term outcome

Conditions: High Bolus Dose of Tirofiban

Summary: the goal of the study to investigate the impact of upstream hbd of tirofiban on short outcome of stemi patient.

* primary percutaneous coronary intervention (ppci) is the gold standard of treatment of st segment elevation myocardial infarction (stemi).1 ppci restores thrombolysis in myocardial infarction flow 3 (timi 3) in over 90% of patients. however ,there remains a small proportion of patients, who continue to exhibit overt impairment of myocardial reperfusion despite successful opening of infarct related epicardiual artery (ira). this phenomenon is called no-reflow, which is largely because of severe microvascular obstruction (mvo). * belonging to the class of glycoprotein iib/iiia inhibitors (gpis), tirofiban, can be useful in primary pci for acute coronary syndrome (acs).1,2the administration of tirofiban is an efficacious treatment option to reduce ischemic events in patients with the acs and/or those undergoing pci.2,3 in most guidelines, abciximab is recommended as the drug of first choice4 due to the finding that tirofiban is less effective than abciximab in platelet inhibition within 60 min of intravenous administration. however, some recent systemic reviews of randomized trials have not demonstrated obvious difference between smgpis (eptifibatide or tirofiban) and abciximab in terms of angiographic, electrocardiographic, and clinical outcomes of patients undergoing primary pci.5,6 tirofiban may provide similar efficacy with an improved safety profile when compared with abciximab, particularly with a high-dose bolus regimen.7,8 in the new guideline, the recommended class of smgpis has changed from iib to iia, but tirofiban remains with a pre-pci indication of iib, b.4 although early treatment was associated with a significantly better timi flow and superior timi myocardial perfusion grades (tmpg) in some trials,9,10 no difference in clinical outcome was found between the 2 strategies in later study.11 one potential cost of administration of gpis could be increased bleeding, although both major bleeding and minor bleeding rate are low in the tirofiban-treated patients..

Eligibility criteria:
inclusion criteria: * - acute stemi patient within 12 hours of chest pain exclusion criteria: * -previous infarction in the same infarct- related artery * isr * resistent cardiogenic shock * known ckd with cr cl less than 60 ml/min * uncontrolled htn more than 180/110 mmhg * suspected aortic dissection * traumatic or prolonged cpr * severe trauma or major surgery within 3 month * active peptic ulcer within past 3 month * known history of coagulopathy
effects of rtms and tdcs on motor function in stroke

Conditions: Stroke; Motor Function

Summary: in this study the investigators aim to investigate the effects of two different types of non-invasive brain stimulation techniques -- repetitive transcranial magnetic stimulation (rtms) and transcranial direct current stimulation (tdcs) on motor function in stroke. this is a cross-over study where subjects will receive 5 sessions of stimulation (each separated by 1 week) -- with either active tdcs and sham rtms, sham tdcs and active rtms or both sham tdcs and rtms.


Eligibility criteria:
inclusion criteria: (1) all subjects must be between the ages of 18-90. exclusion criteria: 1. history of major depression, as defined by beck depression scale 30; 2. any substantial decrease in alertness, language comprehension, or attention that might interfere with understanding instructions for motor testing; 3. contraindications to tms * history of seizures * unexplained loss of consciousness * metal in the head * frequent or severe headaches or neck pain * implanted brain medical devices. 4. contraindications to tdcs * metal in the head * implanted brain medical devices 5. advanced liver, kidney, cardiac, or pulmonary disease; 6. a terminal medical diagnosis consistent with survival \< 1 year; 7. coexistent major neurological or psychiatric disease (to decrease number of confounders); 8. a history of significant alcohol or drug abuse in the prior 6 months; 9. subjects may not be actively enrolled in a separate intervention study targeting stroke recovery and any other clinical trials; 10. subjects with global aphasia and deficits of comprehension 11. pregnancy. female subjects of child bearing potential will be asked to take a pregnancy test. if the pregnancy test is positive, the subject may not enroll in the study. 12. use of neuropsychotropic medications \[healthy subjects only\] additional inclusion criteria for stroke subjects: 1. first-time clinical ischemic or hemorrhagic cerebrovascular events - evidenced by a radiological (or physician's) report 2. weakness, defined as score of less than 55 (out of 66) on arm motor fugl-meyer (fm) scale 3. stroke onset \>6 months prior to study enrollment . additional exclusion criteria for stroke subjects: 1. subjects may not have already received tms and/or tdcs stimulation for stroke; 2. history of epilepsy before stroke or episodes of seizures within the last six months;

Keywords: direct current stimulation magnetic stimulation transcranial stimulation